Dawn Baker

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 491 citations

Fgfr Selectivity, Kinase Inhibitors, Pharmacotherapy +16

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

Neil R. Smith, Dawn Baker, Neil H. James et al. · Clinical Cancer Research · 2010 · 236 citations · Full text

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy

Neil R. Smith, Dawn Baker, Matthew R. Farren et al. · Clinical Cancer Research · 2013 · 134 citations · Full text

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Kevin Sharpe, Grant D. Stewart, Alan Mackay et al. · Clinical Cancer Research · 2013 · 68 citations

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>

David W. Jenkins, Sarah J. Ross, Margaret H. Veldman-Jones et al. · Molecular Cancer Therapeutics · 2012 · 51 citations

Angiogenesis, Novel Therapy, Medicine +13